MapLight Therapeutics, Inc. (MPLT)

MapLight Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	33.47	38.25	79.77
Short-Term Investments	27.01	70.54	-
Cash & Cash Equivalents	60.47	108.8	79.77
Cash Growth	-	36.39%	-
Other Current Assets	12.73	5.81	3.84
Total Current Assets	73.2	114.6	83.6
Property, Plant & Equipment	-	1.21	0.97
Long-Term Investments	-	11.38	0.99
Goodwill and Intangibles	-	6.35	5.61
Other Long-Term Assets	-	3.37	0.23
Total Long-Term Assets	-	22.31	7.81
Total Assets	-	136.92	91.41
Accounts Payable	-	1.91	3.25
Current Debt	-	0.78	0.5
Other Current Liabilities	14.98	13.23	10.95
Total Current Liabilities	14.98	15.92	14.7
Long-Term Debt	-	5.8	5.43
Total Long-Term Liabilities	-	5.8	5.43
Total Liabilities	-	21.72	20.13
Total Debt	6.21	6.58	5.92
Debt Growth	-	11.06%	-
Retained Earnings	-	-199.37	-121.79
Comprehensive Income	-	0.16	-
Shareholders' Equity	-245.06	-193.63	-117.59
Net Cash (Debt)	54.27	102.22	73.85
Net Cash (Debt) Growth	-	38.42%	-
Working Capital	58.22	98.68	68.91

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).